In vitro Evidence of Human Immune Responsiveness Shows the Improved Potential of a Recombinant BCG Strain for Bladder Cancer Treatment

In vitro Evidence of Human Immune Responsiveness Shows the Improved Potential of a Recombinant BCG Strain for Bladder Cancer Treatment

The live attenuated mycobacterial strain BCG, in use as vaccine against tuberculosis, is considered the gold standard for primary therapy of carcinoma in situ of the bladder. Despite its limitations, to date it has not been surpassed by any other treatment. Our group has developed a recombinant BCG...

Full description

Bibliographic Details
Main Authors: Dunia Rodriguez, Cibelly Goulart, Ana C. Pagliarone, Eliane P. Silva, Priscila S. Cunegundes, Ivan P. Nascimento, Ricardo C. Borra, Waldely O. Dias, Aldo Tagliabue, Diana Boraschi, Luciana C. C. Leite
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-06-01
Series:Frontiers in Immunology
Subjects:
recombinant BCG
bladder cancer
human immune cells
immunotherapy
adjuvant
CD4 T cells
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.01460/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2019.01460/full

Similar Items